Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Louis-Brennetot

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Ebiomedicine|March 23, 2020
High CD44 expression is not a prognosis marker in patients with high-risk neuroblastomaCaroline Louis-Brennetot, Olivier Delattre, Isabelle Janoueix-Lerosey
Nucleic Acids Research|January 6, 2017
HMCan-diff: a method to detect changes in histone modifications in cells with different genetic characteristicsHaitham Ashoor, Caroline Louis-Brennetot, Isabelle Janoueix-Lerosey, et al.
Genes, Chromosomes & Cancer|September 13, 2011
The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis: an analysis of 104 tumorsCaroline Louis-Brennetot, Jean-Michel Coindre, Céline Ferreira, et al.
Cell Reports|May 18, 2026
A regulatory circuitry driving a noradrenergic to mesenchymal transition highlights YAP/TAZ as critical players in neuroblastoma plasticityMargot Gautier, Amira Kramdi, Caroline Louis-Brennetot, et al.
Cancers|June 10, 2022
BET and CDK Inhibition Reveal Differences in the Proliferation Control of Sympathetic Ganglion Neuroblasts and Adrenal Chromaffin CellsJessica Sriha, Caroline Louis-Brennetot, Cécile Pierre-Eugène, et al.
Oncogene|January 12, 2018
Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesisLucille Lopez-Delisle, Cécile Pierre-Eugène, Caroline Louis-Brennetot, et al.
Oncotarget|August 28, 2019
ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutationsSimon Durand, Cécile Pierre-Eugène, Olivier Mirabeau, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 22, 2011
MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the boneFanny Dujardin, Matthieu Bui Nguyen Binh, Corinne Bouvier, et al.
Plos One|August 31, 2013
Breakpoint features of genomic rearrangements in neuroblastoma with unbalanced translocations and chromothripsisValentina Boeva, Stéphanie Jouannet, Romain Daveau, et al.
Cancer Research|November 10, 2012
Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastomaAlex Cazes, Caroline Louis-Brennetot, Pierre Mazot, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Ebiomedicine|March 23, 2020
High CD44 expression is not a prognosis marker in patients with high-risk neuroblastomaCaroline Louis-Brennetot, Olivier Delattre, Isabelle Janoueix-Lerosey
Nucleic Acids Research|January 6, 2017
HMCan-diff: a method to detect changes in histone modifications in cells with different genetic characteristicsHaitham Ashoor, Caroline Louis-Brennetot, Isabelle Janoueix-Lerosey, et al.
Genes, Chromosomes & Cancer|September 13, 2011
The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis: an analysis of 104 tumorsCaroline Louis-Brennetot, Jean-Michel Coindre, Céline Ferreira, et al.
Cell Reports|May 18, 2026
A regulatory circuitry driving a noradrenergic to mesenchymal transition highlights YAP/TAZ as critical players in neuroblastoma plasticityMargot Gautier, Amira Kramdi, Caroline Louis-Brennetot, et al.
Cancers|June 10, 2022
BET and CDK Inhibition Reveal Differences in the Proliferation Control of Sympathetic Ganglion Neuroblasts and Adrenal Chromaffin CellsJessica Sriha, Caroline Louis-Brennetot, Cécile Pierre-Eugène, et al.
Oncogene|January 12, 2018
Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesisLucille Lopez-Delisle, Cécile Pierre-Eugène, Caroline Louis-Brennetot, et al.
Oncotarget|August 28, 2019
ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutationsSimon Durand, Cécile Pierre-Eugène, Olivier Mirabeau, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 22, 2011
MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the boneFanny Dujardin, Matthieu Bui Nguyen Binh, Corinne Bouvier, et al.
Plos One|August 31, 2013
Breakpoint features of genomic rearrangements in neuroblastoma with unbalanced translocations and chromothripsisValentina Boeva, Stéphanie Jouannet, Romain Daveau, et al.
Cancer Research|November 10, 2012
Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastomaAlex Cazes, Caroline Louis-Brennetot, Pierre Mazot, et al.
Pageof 2